Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Abstract
BACKGROUND: It is still unknown if serum glial fibrillary acidic protein (GFAP) is a useful marker in frontotemporal lobar degeneration (FTLD). OBJECTIVE: To assess the diagnostic and prognostic value of serum GFAP in a large cohort of patients with FTLD. METHODS: In this retrospective study, performed on 406 participants, we measured serum GFAP concentration with an ultrasensitive Single molecule array (Simoa) method in patients with FTLD, Alzheimer's disease (AD), and in cognitively unimpaired elderly controls. We assessed the role of GFAP as marker of disease severity by analyzing the correlation with clinical variables, neurophysiological data, and cross-sectional brain imaging. Moreover, we evaluated the role of serum GFAP as a prognostic marker of disease survival. RESULTS: We observed significantly higher levels of serum GFAP in patients with FTLD syndromes, except progressive supranuclear palsy, compared with healthy controls, but not compared with AD patients. In FTLD, serum GFAP levels correlated with measures of cognitive dysfunction and disease severity, and were associated with indirect measures of GABAergic deficit. Serum GFAP concentration was not a significant predictor of survival. CONCLUSION: Serum GFAP is increased in FTLD, correlates with cognition and GABAergic deficits, and thus shows promise as a biomarker of disease severity in FTLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, some studies reported elevated blood GFAP in participants with FTD compared to controls [8–18] but others observed no such GFAP increase in FTD [19–22].”
From Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders (2025) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, some investigators [8, 11, 14] but not others [9, 21–23] found that blood GFAP concentrations correlate with clinical markers of disease severity in participants with FTD.”
From Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders (2025) · cites this paper as [11]
In the citing paper
“In previous studies, NfL showed good discriminatory power, in CSF and serum, for the differentiation of FTD from controls (area under the curve (AUC) up to 0.88) [25, 28].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living
Lawton, M. P., & Brody, E. M. (1969) · The Gerontologist · doi:10.1093/geront/9.3_part_1.179 · Cited by 18,540
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Classification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Corticocortical inhibition in human motor cortex.
Kujirai, T., Caramia, M. D., Rothwell, J. C., Day, B. L., Thompson, P. D., Ferbert, A., Wroe, S., Asselman, P., & Marsden, C. D. (1993) · The Journal of Physiology · doi:10.1113/jphysiol.1993.sp019912 · Cited by 3,131 · cited 1×
“ForSICI and ICF, the conditioning stimulus (CS) was adjusted at 70% of the RMT, employing multiple interstimulus intervals (ISIs), including 1, 2, 3 ms for SICI and 7, 10, 15 ms for ICF [47, 48].”
Rossini, P. M., Burke, D., Chen, R., Cohen, L. G., Daskalakis, Z., Di Iorio, R., Di Lazzaro, V., Ferreri, F., Fitzgerald, P. B., George, M. S., et al. (2015) · Clinical Neurophysiology · doi:10.1016/j.clinph.2015.02.001 · Cited by 2,753
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538 · cited 1×
“Thecohortconsistedof282patientsmeetingprob-ableclinicalcriteriaforasyndromeintheFTLD spectrum,namely130bvFTD,48avPPA,24svPPA, 50CBS,and30PSP[21–24].”
Katz, S. (1963) · JAMA · doi:10.1001/jama.1963.03060120024016 · Cited by 2,421 · cited 1×
“…severity was assessed with the FTLD modified Clinical Dementia Rating (FTLD-modified CDR) sum of boxes scale [38], while the level of functional independence was assessed with the Basic Activities of Daily Living (BADL) [39] and the Instrumental Activities of Daily Living (IADL) questionnaires [40].”
Reactive Astrocytes: Production, Function, and Therapeutic Potential
Liddelow, S. A., & Barres, B. A. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.006 · Cited by 2,336
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049 · cited 1×
“In this context, increased GFAP levels have been reported in AD [17–19, 73 An interesting finding was the correlation between SAI and GFAP levels in AD subjects.”
Self-citation
Research works printed but not linked: 4
- Meeter LH, 2017, Nat Rev Neurol, 19, 109
- Abu-Rumeileh S, 2019, Alzheimers Res Ther, 12, 1
- Novelli G, 1970, Arch Psicol Neurol Psichiatr, 47, 278
- Novelli G, 1986, Arch Psicol Neurol Psichiatr, 47, 477
Cited by
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045
“74,79,80 Concentrations were also elevated in Lewy body dementia compared with both controls and people with Parkinson’s disease.”
Self-citationBlood GFAP as an emerging biomarker in brain and spinal cord disorders
Abdelhak, A., Foschi, M., Abu-Rumeileh, S., Yue, J. K., D’Anna, L., Huss, A., Oeckl, P., Ludolph, A. C., Kuhle, J., Petzold, A., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00616-3 · Cited by 807
Benedet, A. L., Milà-Alomà, M., Vrillon, A., Ashton, N. J., Pascoal, T. A., Lussier, F., Karikari, T. K., Hourregue, C., Cognat, E., Dumurgier, J., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3671 · Cited by 638
Self-citationGFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Kim, K. Y., Shin, K. Y., & Chang, K.-A. (2023) · Cells · doi:10.3390/cells12091309 · Cited by 309
“7, 154) 164 (125, 223) Benussi, 2020 [37] Italy HC/AD 61 (20.”
Baiardi, S., Quadalti, C., Mammana, A., Dellavalle, S., Zenesini, C., Sambati, L., Pantieri, R., Polischi, B., Romano, L., Suffritti, M., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01093-6 · Cited by 193
“Our FTD cohort included both GRN carriers (10% of cases) and patients with severe disease (7% with CRD-FTLD ≥ 3), two conditions known to be associated with increased biomarker levels [49, 51].”
BackgroundChallenges in the practical implementation of blood biomarkers for Alzheimer’s disease
Schöll, M., Verberk, I. M. W., del Campo, M., Delaby, C., Therriault, J., Chong, J. R., Palmqvist, S., & Alcolea, D. A. (2024) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2024.07.013 · Cited by 161
Ashton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05253-y · Cited by 142
Self-citationBlood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist
Alcolea, D. A., Beeri, M. S., Rojas, J. C., Gardner, R. C., & Lleó, A. (2023) · Neurology · doi:10.1212/wnl.0000000000207193 · Cited by 130
“High concentrations of plasma GFAP have also been reported in patients with frontotemporal lobar degeneration (FTLD)–related syndromes but to a lesser extent than those in patients with AD.(28,29)”
ResultAshton, N. J., Suárez‐Calvet, M., Karikari, T. K., Lantero‐Rodriguez, J., Snellman, A., Sauer, M., Simrén, J., Minguillon, C., Fauria, K., Blennow, K., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12168 · Cited by 121
Self-citationHeimfarth, L., Passos, F. R. S., Monteiro, B. S., Araújo, A. A. D. S., Quintans‐Júnior, L. J., & Quintans, J. D. S. S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108624 · Cited by 115
Shen, X., Huang, S., Cui, M., Zhao, Q., Guo, Y., Huang, Y., Zhang, W., Ma, Y., Chen, S.-D., Zhang, Y.-R., et al. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad018 · Cited by 102
Oeckl, P., Anderl-Straub, S., Von Arnim, C. A. F., Baldeiras, I., Diehl-Schmid, J., Grimmer, T., Halbgebauer, S., Kort, A. M., Lima, M., Marques, T. M., et al. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328547 · Cited by 94
The dynamics of plasma biomarkers across the Alzheimer’s continuum
Guo, Y., Shen, X.-N., Wang, H.-F., Chen, S.-D., Zhang, Y.-R., Chen, S.-F., Cui, M., Cheng, W., Dong, Q., Ma, T., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01174-0 · Cited by 95
Zhu, N., Santos-Santos, M., Illán-Gala, I., Montal, V., Estellés, T., Barroeta, I., Altuna, M., Arranz, J., Muñoz, L., Belbin, O., et al. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00275-w · Cited by 86
“Although previous studies did not detect changes of blood GFAP level in FTD [10, 12, 13], some studies have observed elevated pGFAP in all different FTD subgroups [24,25, 26].”
BackgroundResultInfluentialDifferential diagnostic performance of a panel of plasma biomarkers for different types of dementia
Thijssen, E. H., Verberk, I. M. W., Kindermans, J., Abramian, A., Vanbrabant, J., Ball, A. J., Pijnenburg, Y., Lemstra, A. W., van der Flier, W. M., Stoops, E., et al. (2022) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12285 · Cited by 86
Motawi, T. K., Al-Kady, R. H., Abdelraouf, S. M., & Senousy, M. A. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110002 · Cited by 88
Chadarevian, J. P., Hasselmann, J., Lahian, A., Capocchi, J. K., Escobar, A., Lim, T. E., Le, L., Tu, C., Nguyen, J., Kiani Shabestari, S., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.05.023 · Cited by 83
“48 Analysis of blood plasma revealed that elevated levels of GFAP within the periphery could also be readily detected, which were significantly reduced in microglial-engrafted hFIRE-HPC mice (Figure 4J).”
BackgroundSimrén, J., Weninger, H., Brum, W. S., Khalil, S., Benedet, A. L., Blennow, K., Zetterberg, H., & Ashton, N. J. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12806 · Cited by 84
Self-citationPark, Y., Nirajan, K. C., Paneque, A., & Cole, P. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126295 · Cited by 86
“In other words, an increase in blood GFAP may be coupled with heightened impulsivity and decision-making deficits, indicating a more severe clinical progression of FTLD [71,72].”
BackgroundLin, J., Ou, R., Li, C., Hou, Y., Zhang, L., Wei, Q., Pang, D., Liu, K., Jiang, Q., Yang, T., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03120-1 · Cited by 79
“…level of plasma GFAP in PD [10] and other neurodegenerative disorders such as AD [23], Lewy body dementia [11], and frontotemporal dementia [24], as well as other neurological disorders such as traumatic brain injury (TBI) [5], cerebrovascular accidents [6], and neuroinflammatory diseases…”
BackgroundKatisko, K., Cajanus, A., Huber, N., Jääskeläinen, O., Kokkola, T., Kärkkäinen, V., Rostalski, H., Hartikainen, P., Koivisto, A. M., Hannonen, S., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326487 · Cited by 65
Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline
Peretti, D. E., Boccalini, C., Ribaldi, F., Scheffler, M., Marizzoni, M., Ashton, N. J., Zetterberg, H., Blennow, K., Frisoni, G. B., & Garibotto, V. (2024) · Brain · doi:10.1093/brain/awae211 · Cited by 72
“24,25 Consequently, the NIA-AA has included GFAP as a staging biomarker for neuroin-flammation in the abovementioned revised criteria.”
Self-citationPlasma biomarkers for neurodegenerative disorders: ready for prime time?
Balogun, W. G., Zetterberg, H., Blennow, K., & Karikari, T. K. (2023) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000851 · Cited by 66
Self-citationA data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia
van der Ende, E. L., Bron, E. E., Poos, J. M., Jiskoot, L. C., Panman, J. L., Papma, J. M., Meeter, L. H. H., Dopper, E. G. P., Wilke, C., Synofzik, M., et al. (2021) · Brain · doi:10.1093/brain/awab382 · Cited by 63
“…heavy chain (pNfH), which reflect neuroaxonal degeneration 6-9 ; neuronal pentraxin 2 (NPTX2), a marker of synapse integrity 10,11 ; glial fibrillary acidic protein (GFAP), a marker of astrogliosis 12-14 ; and complement factors C1q and C3b, which reflect activation of the complement system.”
Self-citationNeuroimaging and biomarker evidence of neurodegeneration in asthma
Rosenkranz, M. A., Dean, D., Bendlin, B. B., Jarjour, N. N., Esnault, S. J., Zetterberg, H., Heslegrave, A., Evans, M. D., Davidson, R. J., & Busse, W. W. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.09.010 · Cited by 52
Self-citationBiomarkers of Alzheimer’s disease: Past, present and future clinical use
Georgakas, J. E., Howe, M. D., Thompson, L. I., Riera, N. M., & Riddle, M. C. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100063 · Cited by 58
Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis
Katzeff, J. S., Bright, F., Phan, K., Kril, J. J., Ittner, L. M., Kassiou, M., Hodges, J. R., Piguet, O., Kiernan, M. C., Halliday, G. M., et al. (2022) · Brain · doi:10.1093/brain/awac077 · Cited by 48
Youssef, P., Hughes, L., Kim, W. S., Halliday, G. M., Lewis, S. J. G., Cooper, A., & Dzamko, N. (2023) · Scientific Reports · doi:10.1038/s41598-023-32480-0 · Cited by 46
French, S. R., Meyer, B. P., Arias, J. C., Levendovszky, S. R., & Weinkauf, C. C. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70104 · Cited by 53
Serum GFAP – reference interval and preanalytical properties in Danish adults
Tybirk, L., Hviid, C. V. B., Knudsen, C. S., & Parkner, T. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0646 · Cited by 48
Plasma GFAP as a prognostic biomarker of motor subtype in early Parkinson’s disease
Che, N.-N., Ou, R., Li, C., Zhang, L., Wei, Q., Wang, S., Jiang, Q., Yang, T., Xiao, Y., Lin, J., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00664-8 · Cited by 41
“GFAPservesasabiomarkerofreactiveastrogliosis,exhibiting elevated levelsinplasmaandcerebrospinal fl uid(CSF)inneurodegenerativediseases such as Alzheimer ’ s disease (AD) 24,25 , dementia with Lewy bodies 26 , fron-totemporal lobar degeneration 27 , and PD 28 .”
New insights and therapeutic opportunities for progranulin-deficient frontotemporal dementia
Amin, S., Carling, G., & Gan, L. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.10.001 · Cited by 38
Bolsewig, K., Hok-A-Hin, Y. S., Sepe, F. N., Boonkamp, L., Jacobs, D., Bellomo, G., Paoletti, F. P., Vanmechelen, E., Teunissen, C. E., Parnetti, L., et al. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220318 · Cited by 36
Chatterjee, P., Doré, V., Pedrini, S., Krishnadas, N., Thota, R. N., Bourgeat, P., Ikonomović, M. D., Rainey‐Smith, S. R., Burnham, S. C., Fowler, C. J., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220908 · Cited by 39
Benussi, A., Huber, H., Tan, K., Cantoni, V., Rivolta, J., Cotelli, M. S., Benedet, A. L., Blennow, K., Zetterberg, H., Ashton, N. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14482 · Cited by 38
Self-citationBlood biomarkers in frontotemporal dementia: Review and meta-analysis
Ntymenou, S., Tsantzali, I., Kalamatianos, T., Voumvourakis, K. I., Kapaki, E., Tsivgoulis, G., Stranjalis, G., & Paraskevas, G. P. (2021) · Brain Sciences · doi:10.3390/brainsci11020244 · Cited by 31
“A great number of studies have focused on micro-RNAs (mRNAs) in FTD, with their results showing a potential use of mRNAs both as a diagnostic tool and as a staging tool of FTD [54].”
Mao, S., Teng, X., Li, Z., Zu, J., Zhang, T., Xu, C., & Cui, G. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148271 · Cited by 34
Brain injury markers in new-onset seizures in adults: A pilot study
Eriksson, H., Banote, R. K., Larsson, D., Blennow, K., Zetterberg, H., & Zelano, J. (2021) · Seizure · doi:10.1016/j.seizure.2021.08.012 · Cited by 30
“Increased GFAP levels reflect astroglial activation or injury across a broad range of acute and chronic neurological diseases [7-11].”
Self-citationBlood-Based Biomarkers in Frontotemporal Dementia: A Narrative Review
Liampas, I., Kyriakoulopoulou, P., Karakoida, V., Kavvoura, P. A., Sgantzos, M. N., Bogdanos, D. P., Stamati, P., Dardiotis, E., & Siokas, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111838 · Cited by 25
“…with rates of cognitive decline and temporal atrophy in those with FTD (AD as well) and presymptomatic GRN and C9orf72 mutation carriers [54,125–127, 130, Overall, blood GFAP appears to be a non-specific index of neurodegeneration, although amyloid pathology may present stronger…”
BackgroundResultSolje, E., Benussi, A., Buratti, E., Remes, A. M., Haapasalo, A., & Borroni, B. (2021) · Diagnostics · doi:10.3390/diagnostics11050788 · Cited by 29
“Recently, GFAP presence in serum, which reflects astrocytosis, has been shown to be elevated both in AD [69] and in FTD patients [70,71], as well as in patients with pre-symptomatic stages of AD [72].”
BackgroundSelf-citationKatisko, K., Huber, N., Kokkola, T., Hartikainen, P. H., Krüger, J., Heikkinen, A.-L., Paananen, V., Leinonen, V., Korhonen, V. E., Helisalmi, S., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01091-8 · Cited by 27
Self-citationÁlvarez‐Sánchez, L., Peña‐Bautista, C., Baquero, M., & Cháfer‐Pericás, C. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215093 · Cited by 26
Digital Immunoassay for Proteins: Theory, Methodology, and Clinical Applications
Liu, X., Zhang, Q., Zong, C., & Gai, H. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c05421 · Cited by 24
Traub, J., Otto, M., Sell, R., Homola, G. A., Steinacker, P., Oeckl, P., Morbach, C., Frantz, S., Pham, M., Störk, S., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13986 · Cited by 27
Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy
Huang, S., Chen, S., Cui, M., Zhao, M., Shen, X., Guo, Y., Zhang, Y.-R., Zhang, W., Wang, H.-F., Huang, Y., et al. (2023) · Movement Disorders · doi:10.1002/mds.29339 · Cited by 23
“Previous relevant studies are very few and inconsistent, demonstrating a low accuracy of plasma GFAP in PSP diagnosis.(27,29,32) Except for the small sample size, the proportion of unreported amyloid-positive controls may contribute to the contradictory findings, considering the correlation between plasma GFAP and Aβ…”
ResultComeau, D., Martin, M., Robichaud, G. A., & Chamard-Witkowski, L. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1233192 · Cited by 24
Sheth, U., Öijerstedt, L., Heckman, M. G., White, L. J., Heuer, H. W., Lario Lago, A., Forsberg, L. K., Faber, K. M., Foroud, T. M., Rademakers, R., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00821-4 · Cited by 20
“Similarly, some investigators [8, 11, 14] but not others [9, 21–23] found that blood GFAP concentrations correlate with clinical markers of disease severity in participants with FTD. Small cohort sizes and the heterogeneity of FTD spectrum disorders may underlie these discrepancies.”
Eratne, D., Kang, M. J., Lewis, C. C., Dang, C., Malpas, C. B., Ooi, S., Brodtmann, A. G., Darby, D., Zetterberg, H., Blennow, K., et al. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2024.123291 · Cited by 23
Self-citationAdvances in the treatment and management of frontotemporal dementia
Benussi, A., & Borroni, B. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2228491 · Cited by 19
Self-citationPerivascular spaces, plasma GFAP, and speeded executive function in neurodegenerative diseases
Andriuta, D., Ottoy, J., Ruthirakuhan, M. T., Feliciano, G. J., Dilliott, A. A., Hegele, R. A., Gao, F., McLaughlin, P. M., Rabin, J. S., Alexander, M. W., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14081 · Cited by 19
“25 Plasma GFAP has been associated with fron-totemporal dementia (FTD), 26 cerebral small vessel disease, 27 AD, and vascular pathology.”
Self-citationEarly Diagnosis of Alzheimer’s Disease: Moving Toward a Blood-Based Biomarkers Era
Tao, Q., Lin, R.-R., & Wu, Z. (2023) · Clinical Interventions in Aging · doi:10.2147/cia.s394821 · Cited by 23
“It has been reported that both CSF and serum GFAP concentrations were significantly increased in AD compared to cognitively unimpaired (CU) participants and correlates with cognitive impairment.30,31 Furthermore, plasma GFAP levels were significantly elevated in Aβ+ CU participants compared to Aβ- CU participants,32 a…”
BackgroundImpaired glymphatic system in genetic frontotemporal dementia: a GENFI study
Premi, E., Diano, M., Mattioli, I., Altomare, D., Cantoni, V., Bocchetta, M., Gasparotti, R., Buratti, E., Pengo, M., Bouzigues, A., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae185 · Cited by 20
“17 In this view, we also reported a mild negative association between glymphatic function and expected age at onset of symptoms and between glymphatic function and markers of neurodegeneration, such as NfL, 25,26,33 although not statistically significant.”
BackgroundSelf-citationRamos‐Campoy, O., Lladó, A., Bosch, B., Ferrer, M., Pérez‐Millan, A., Vergara, M., Molina‐Porcel, L., Fort‐Aznar, L., Gonzalo, R., Moreno, F., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02969-2 · Cited by 21
“reported to be increased in AD and FTD brain, but also in plasma or serum [58, 59, 60].”
BackgroundHeller, C., Chan, E., Foiani, M. S., Todd, E., Russell, L. L., Greaves, C. V., Heslegrave, A. J., Warren, J. D., Zetterberg, H., Bocchetta, M., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-325085 · Cited by 15
“5 Here we found increased GFAP levels with lower temporal lobe volumes suggesting that as the disease progresses the concentration of GFAP rises.”
Self-citationReyes‐Leiva, D., Dols‐Icardo, O., Sirisi, S., Cortés‐Vicente, E., Turón‐Sans, J., de Luna, N., Blesa, R., Belbin, O., Montal, V., Alcolea, D. A., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.750543 · Cited by 19
“This protein can also be accurately measured in the blood with new ultrasensitive technology (189).”
BackgroundExperimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration
Giunta, M., Solje, E., Gardoni, F., Borroni, B., & Benussi, A. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s262352 · Cited by 18
Self-citationRamalingam, M., Jang, S., Hwang, J., Cho, H., Kim, B. C., & Jeong, H. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04306-5 · Cited by 16
“GFAP is a marker of astrogliosis and a key marker in cognitive impairment assessments [67].”
Chu, M., Yue, A., Yan, S., Yu, B., He, Q., Chen, Y., Hou, J., Nan, H., Ye, H., Nie, B., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70561 · Cited by 13
“28 32–37 Asaspecificmarkerofastro-cytic activation and neuroinflammation, 38 GFAP levels may reflect glymphatic and BBB integrity.”
Frontotemporal dementia as a consequence of GRN mutations: From disease cause to models to therapies
Salzano, S., Bertasini, C., Haghighi, S. T., Lundkvist, J., Wahlberg, L. U., Chiamulera, C., Vattemi, G. N. A., Gardoni, F., & Paolone, G. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107957 · Cited by 16
Saraceno, C., Cervellati, C., Trentini, A., Crescenti, D., Longobardi, A., Geviti, A., Bonfiglio, N. S., Bellini, S., Nicsanu, R., Fostinelli, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158354 · Cited by 11
“Recently, higher levels of Glial Fibrillary Acid Protein (GFAP) and Neurofilament Light chain (NfL) in the serum of FTD and AD patients compared to healthy controls were reported [39–42].”
ResultSelf-citationHsiao‐Nakamoto, J., Chiu, C., VandeVrede, L. A., Ravi, R., Vandenberg, B., Groot, J. D., Tsogtbaatar, B., Fang, M., Auger, P., Gould, N. S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.09.579529 · Cited by 12
Suresh, S., Maffei, L., Bauermeister, S., & Raymont, V. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251408510 · Cited by 12
Chatzidimitriou, E., Ioannidis, P., Aretouli, E., Papaliagkas, V. T., & Μoraitou, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813810 · Cited by 19
“…and predicting disease progression in FTD. Higher pGFAP concentrations have been associated with greater functional impairment and disease severity in other recent studies, as well, further solidifying the role of neuroinflammation in the pathogenesis and prognosis of frontotemporal dementia [64].”
BackgroundMulti-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer’s Disease
Bhalala, O. G., Watson, R., & Yassi, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021231 · Cited by 11
“Of note, a rise in plasma GFAP levels is also seen in Lewy body dementia [157] and FTD [165], suggesting that plasma GFAP levels are reflective of the reactive astrogliosis occurring in neurodegeneration more broadly.”
BackgroundRelationships between PET and blood plasma biomarkers in corticobasal syndrome
Singh, N. A., Alnobani, A., Graff‐Radford, J., Machulda, M. M., Mielke, M. M., Schwarz, C. G., Senjem, M. L., Jack, C. R., Lowe, V. J., Kanekiyo, T., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13914 · Cited by 9
Blood biomarker profiles in young-onset neurocognitive disorders: A cohort study
Bhalala, O. G., Beamish, J., Eratne, D., Summerell, P., Porter, T., Laws, S. M., Kang, M. J., Huq, A. J., Chiu, W.-H. M., Cadwallader, C. J., et al. (2025) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674241312805 · Cited by 9
“Overall, our findings support the hypothesis that GFAP may be a marker in a number of neurodegenerative conditions (Abdelhak et al., 2022; Benussi et al., 2020; Cicognola et al., 2021; Oeckl et al., 2019).”
Altomare, D., Libri, I., Alberici, A., Rivolta, J., Padovani, A., Ashton, N. J., Zetterberg, H., Blennow, K., & Borroni, B. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01474-z · Cited by 11
“Aβ 42 /Aβ 40 , NfL, and GFAP were analyzed using a commercial Simoa multiplex assay [31–33].”
MethodSelf-citationBiomarkers of vascular cognitive impairment
Zimnitskaya, O. V., Mozheyko, E. Y., & Петрова, М. М. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2677 · Cited by 8
Structural flexibility and heterogeneity of recombinant human glial fibrillary acidic protein (GFAP)
Gogishvili, D., Illes‐Toth, E., Harris, M. J., Hopley, C., Teunissen, C. E., & Abeln, S. (2024) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.26656 · Cited by 8
“30 Moreover, increased levels of plasma GFAP have been detected in cognitively healthy individuals at risk of AD, indicating early astrocytic damage in the presymptomatic stages of the disease.”
BackgroundPreclinical and Prodromal Frontotemporal Dementia: Challenges and Opportunities
Palacino, F., Manganotti, P., & Benussi, A. (2025) · International Journal of Translational Medicine · doi:10.3390/ijtm5040052 · Cited by 7
Self-citationde Boer, S. C. M., Fenoglio, C., Arighi, A., Wissink, L., Riedl, L., Rue, I., Landín-Romero, R., Matis, S., Chatterton, Z., Halliday, G. M., et al. (2025) · BMJ Neurology Open · doi:10.1136/bmjno-2024-001007 · Cited by 10
Huang, J., Pang, X., Yang, H., Gao, C., Wang, D., Sun, Y., Taishi, Y., & Pang, C.-Y. (2024) · Current Alzheimer Research · doi:10.2174/0115672050333760241010061547 · Cited by 8
Cotelli, M. S., Tarantino, B., Tan, K., Huber, H., Cantoni, V., Bracca, V., Gasparotti, R., Premi, E., Logroscino, G., Benedet, A. L., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14558 · Cited by 6
“The few previous works on the role of GFAP in FTLD showed conflicting results, 22,38 and even in the present study we did not find a significant association between plasma GFAP levels and survival rate.”
Self-citationGiannakis, A., Konitsiotis, S., & Sioka, C. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02955-7 · Cited by 7
“(Benussi et al. 2020) Notably, the nfvPPA subgroup exhibited significantly elevated GFAP levels compared to both PSP and CBS.”
InfluentialClinical features and biomarkers of semantic variant primary progressive aphasia with MAPT mutation
Xu, J., Xia, Y., Meng, M., Liu, F., Che, P., Zhang, Y., Wang, Y., Cai, L., Qin, W., & Zhang, N. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01176-y · Cited by 6
“In addition, recent studies reported that serum GFAP levels were significantly higher in patients with FTLD than in healthy controls and were correlated with cognitive dysfunction and disease severity [51].”
BackgroundGhaderian, M., Shahbazi‐Gahrouei, D., Nikzad, S., Didehban, E., Hafezi, H., Laher, I., Beigi, F. H., Shahbazi‐Gahrouei, S., & Boustani, T. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.04.016 · Cited by 5
“Additionally, volume reduction of white matter and grey matter was positively associated with s-GFAP levels (Benussi et al., 2020).”
Li, M., Liu, H., Xu, M., Yu, B., Guo, M., Wang, X., Shi, G., & Zhou, R. (2024) · Clinical Interventions in Aging · doi:10.2147/cia.s448180 · Cited by 5
Sensi, S. L., Russo, M., & Tiraboschi, P. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85538-9.00015-8 · Cited by 7
Benussi, A., & Vucic, S. (2025) · Clinical Neurophysiology · doi:10.1016/j.clinph.2025.2111459 · Cited by 4
Self-citationCetindag, A. C., Schipke, C. G., Esselmann, H., Kruse, N., Wiltfang, J., Schneider, A., Fließbach, K., Miklitz, C., Maier, F., Büerger, K., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100544 · Cited by 5
Cerebrospinal fluid YKL‐40 level evolution is associated with autoimmune encephalitis remission
Dorcet, G., Bénaiteau, M., Pariente, J., Ory‐Magne, F., Cheuret, E., Rafiq, M., Brooks, W. H., Puissant‐Lubrano, B., Fortenfant, F., Renaudineau, Y., et al. (2023) · Clinical & Translational Immunology · doi:10.1002/cti2.1439 · Cited by 4
Li, X., Sun, Y., Chen, L., & Li, Y. (2025) · Rejuvenation Research · doi:10.1177/15491684251379234 · Cited by 3
“31 Previous studies have found that elevated levels of GFAP are associated with POCD following both cardiac and noncardiac surgeries, indicating its potential as a bio-marker for brain injury and cognitive impairment.”
Liu, Y., Wang, J., Ning, F., Wang, G., & Xie, A. (2024) · Clinical and Translational Science · doi:10.1111/cts.70111 · Cited by 6
Hanin, A., Quadrio, I., Beaudeux, J., & Lamari, F. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13896-w · Cited by 2
“As observed in other neurodegenerative disorders, higher GFAP levels in FTD were associated with worse cognitive performance, greater brain atrophy, and poorer functional outcome [66, 86, 94].”
Brain-derived neurotrophic factor and its relationship to known biomarkers of Alzheimer's disease
Kueck, P. J., Honea, R. A., Kemna, R. E., Burns, J. M., & Morris, J. K. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251362487 · Cited by 2
Utilizing databases for astrocyte secretome research
Afridi, R., Lee, W., Kim, J., & Suk, K. (2023) · Expert Review of Proteomics · doi:10.1080/14789450.2023.2285311 · Cited by 2
“Identifying and characterizing the secretory profile of astrocytes holds the potential to identify diagnostic and prognostic biomarkers, as well as therapeutic targets for various neurological conditions [9–11].”
BackgroundTrajectories of blood-based protein biomarkers in chronic traumatic brain injuryPreprint
Hicks, A. J., Plourde, J., Selmanovic, E., de Souza, N. L., Blennow, K., Zetterberg, H., & Dams-O’Connor, K. (2025) · medRxiv · doi:10.1101/2025.02.16.25322303 · Cited by 2
“; https://doi.org/10.1101/2025.02.16 .25322303 doi: medRxiv preprint performance on cognitive tests, 139,170,171 a steeper rate of cognitive decline, 174,175 worse functional status, 170 and higher rates of eventual conversion to dementia.”
InfluentialSelf-citationClinicopathological and prognostic correlations of plasma biomarkers in neurodegenerative diseasesPreprint
Malpetti, M., Chouliaras, L., Murley, A. G., Swann, P., Coyle-Gilchrist, I. T. S., Bevan-Jones, W. R., Savulich, G., Perquin, M. N., Wiggins, J., Bowns, L., et al. (2025) · medRxiv · doi:10.64898/2025.12.07.25341788 · Cited by 2
Self-citationDelaby, C., & Lehmann, S. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-1731 · Cited by 1
From scaffold to effector: reframing GFAP in neurodegeneration
Lu, Y.-H., Zhu, X., Li, S., Zhang, F., Cai, C.-B., Tian, M., Zhu, Y., Zeng, L.-H., Tan, J., Changyin, Y., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.02.051 · Cited by 1
Diagnosis and management of frontotemporal dementia: a narrative review
Cenacchi, V., Lombardo, T., Palacino, F., Cattaruzza, T., Manganotti, P., & Benussi, A. (2026) · Neurodegenerative Disease Management · doi:10.1080/17582024.2026.2687481 · Cited by 2
Self-citationDelaby, C., & Lehmann, S. (2026) · Laboratory Service · doi:10.17116/labs20261502137 · Cited by 1
Benussi, A., Bracca, V., Premi, E., Cantoni, V., Palacino, F., Saccavini, A., Cotelli, M. S., Binetti, G. G., Manenti, R., Alberici, A., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71722 · Cited by 1
Self-citationProfit vs. nonprofit: does either have a competitive edge?
Mangan, D. (1998) · PubMed · Cited by 1
Che, N., Ou, R., Li, C., Zhang, L., Wei, Q., Wang, S., Jiang, Q., Yang, T., Xiao, Y., Lin, J., et al. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.106732 · Cited by 1
Biomarkers used in Alzheimer's disease diagnosis
Mishra, S. K., Singh, R., Chang, H., Obaid, A. A., & Singh, S. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15540-6.00013-6 · Cited by 1
Fluid and Imaging Markers of Frontotemporal Lobar Degeneration
Prinse, F., Houwer, J. F. H. D., Dopper, E. G. P., & Seelaar, H. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_9 · Cited by 1
Skowrońska, M., Cudna, A., Pakuła, B., Lebiedzińska, M., Janikiewicz, J., Dobosz, A. M., Jakubek, P., Wydrych, A., Cwyl, M., Dobrzyń, A., et al. (2025) · Cells · doi:10.3390/cells14221801 · Cited by 1
“In conditions like FTD, GFAP levels may be higher than those seen in diseases such as AD or PD, and GFAP levels have been shown to correlate with disease severity [7,28].”
Zhu, N., Santos‐Santos, M., Illán‐Gala, I., Montal, V., Estellés, T., Barroeta, I., Altuna, M., Arranz, J., Muñoz, L., Belbin, O., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-958956/v1
Metadata
- Authors
- Benussi, A., Ashton, N. J., Karikari, T. K., Gazzina, S., Premi, E., Benussi, L., Ghidoni, R., Rodriguez, J. L., Emeršič, A., Binetti, G., Fostinelli, S., Giunta, M., Gasparotti, R., Zetterberg, H., Blennow, K., & Borroni, B.
- Affiliations
- University of Brescia (IT)
- King's College London (GB)
- University of Gothenburg (SE)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Centro San Giovanni di Dio Fatebenefratelli (IT)
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
- Ljubljana University Medical Centre (SI)
- Corresponding author
- Borroni, Barbara
- ORCID
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2020-08-14
- Volume
- 77
- Issue
- 3
- Pages
- 1129-1141
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W3049719602
- Cited by
- 113
- References
- 80
- Citations by year
- 2026: 11 · 2025: 24 · 2024: 22 · 2023: 21 · 2022: 16 · 2021: 17 · 2020: 1
- FWCI
- 9.97
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Funders
- Alzheimer's Drug Discovery Foundation (2016862, FO2017-0243, 201809, 2017-00915, #ALFGBG-715986, 201809–2016862, JPND2019-466-236, 201809-2016615, #RDAPB‐201809‐2016615, AF-742881)
- EU Joint Programme – Neurodegenerative Disease Research (JPND2019-466-236)
- European Commission (JPND2019‐466‐236)
- Ministero della Salute (2018-)
- Hjärnfonden (FO2017‑0243, FO2017, ALFGBG-715986, JPND2019-466-236)
- Vetenskapsrådet (2017-00915, (#ALFGBG-715986, 681712, 2018-, JPND2019-466-236, FO2017-0243, 2018-02532)
- UK Dementia Research Institute (#2017-00915)
- H2020 European Research Council (681712)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- glial fibrillary acidic protein, serum biomarkers
- MeSH terms
- Aged, Aged, 80 and over, Female, Glial Fibrillary Acidic Protein, Humans, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, Biomarkers, Frontotemporal Lobar Degeneration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.